The Supplement Portfolio Rebalance Nobody Saw Coming
In 2015, resveratrol was the compound of choice among high-income earners seeking to extend healthspan. It had the narrative: French Paradox, sirtuins, NAD+ activation. A bottle of premium red wine or a resveratrol supplement became synonymous with "intelligent aging" in certain Manhattan and San Francisco circles.
By late 2024, something shifted. Not gradually. Abruptly. The same cohort that once religiously tracked their polyphenol intake—measuring wine consumption in terms of ORAC values and trans-resveratrol percentages—began liquidating those stacks. They sold the narrative along with the supplements.
What replaced it was not another compound. It was continuous data.
The Wearable-First Economy and Why Compounds Fell Out of Favor
The trigger wasn't new science disproving resveratrol. The trigger was something simpler: the arrival of consumer-grade continuous glucose monitors (CGMs), heart rate variability (HRV) trackers, and sleep architecture wearables sophisticated enough to act as real-time feedback devices rather than mere logging tools.
When you can see—in real time, with 15-minute granularity—how your glucose responds to a specific meal, how your autonomic nervous system shifts with stress, or how your deep sleep pressure recovers night-to-night, supplement protocols based on averages and population-level effect sizes start to feel abstract.
Oura Ring, Whoop, and increasingly accessible CGM data (Freestyle Libre is now over-the-counter in the US) created a new optimization paradigm: interventions must show *individual* effect, measured *immediately*, or they exit the protocol.
Resveratrol, by contrast, shows benefits primarily in aging biomarkers tracked across years. Its effect on HRV next Thursday? Negligible. Its effect on morning glucose variance? Not detectable in a 30-day window. Its effect on sleep architecture tonight? Zero.
What the Clinical Evidence Actually Shows About Polyphenols
The science on resveratrol is not weak. It's just slow-acting and population-dependent.
A 2019 meta-analysis by Sahebkar et al. in *Nutrients* found that resveratrol supplementation reduced systolic blood pressure by 2-3 mmHg across 17 randomized trials—a real effect, but modest and visible only across months or years of intervention and measurement. A 2021 Cochrane review on polyphenol supplements and cardiovascular outcomes was less encouraging, flagging significant heterogeneity in trials and publication bias concerns.
More recently, a 2023 study in *Cell Metabolism* (Hubbard et al.) examined resveratrol's effects on NAD+ metabolism in humans. The finding: oral resveratrol does increase NAD+ precursors in blood, but the tissue-level bioavailability is poor. Liver metabolism substantially reduces the active fraction.
For a finance professional pulling real-time CGM and HRV data daily, these effect sizes and bioavailability constraints are disqualifying. The signal-to-noise ratio is too low.
The Protocol Migration: From Stacks to Dashboards
What Wall Street's quantitative biohackers discovered is that their time was better spent on interventions that produce *visible, measurable changes within days*, not years.
The new hierarchy looks like this:
- Tier 1: Behavioral interventions with rapid feedback loops. Cold exposure protocols (measurable HRV increase within 72 hours). Intermittent fasting windows (immediate CGM response visible in 1-2 days). Specific sleep timing protocols (detectable via Oura Ring architecture metrics).
- Tier 2: Supplements with week-to-month feedback visibility. Magnesium glycinate for sleep latency (HRV and REM latency changes visible in 10-14 days). Creatine monohydrate for cognitive processing speed (measurable via response-time testing or reaction tasks, 4-6 weeks). Sodium-glucose cotransporter inhibitors (SGLT2 inhibitors, in medical contexts) for glucose stability (CGM variance reduction visible in 2-3 weeks).
- Tier 3: True longevity compounds. These are deprioritized unless they show *any* measurable short-term biomarker change. Resveratrol stays, if at all, for its theoretical NAD+ contribution—not because current data supports individual-level efficacy.
This is not pseudoscience. This is rational resource allocation. If a supplement's only evidence comes from population-level aging studies, its ROI for a 45-year-old trader trying to optimize quarterly performance is precisely zero.
Why Wearable Feedback Creates a New Bias
There is an irony worth naming: the shift toward wearable-driven optimization creates its own distortions.
The interventions that *look* effective on a dashboard—the ones that produce visible changes in HRV, sleep staging, or glucose variance—are often acute, short-term responses. A cold plunge produces an immediate sympathetic surge followed by parasympathetic rebound. It's visible. It feels like optimization. But the long-term healthspan benefit of repeated cold exposure, while promising, remains incompletely understood.
By contrast, interventions that deliver slow, invisible benefits—consistent antioxidant intake, steady micronutrient sufficiency, moderate consistent exercise—stop getting prioritized because they don't trigger the dashboard alerts.
A 2023 commentary in *Nature Aging* (Kennedy and Lamming) explicitly warned against this: "The accessibility of real-time biomarker data creates an illusion of understanding that may eclipse slower, more robust interventions." Wearable optimization can become high-frequency noise mistaken for signal.
The Supplement Efficacy Problem Underlying This Shift
Honestly, the deeper issue is that most oral supplements—regardless of mechanism—show poor bioavailability and high inter-individual variability.
A person's genetic polymorphisms in cytochrome P450 enzymes, their gut microbiota composition, their gastric pH, and their liver function all dictate whether a resveratrol supplement reaches systemic circulation intact or gets largely metabolized before absorption. Two finance professionals taking the same resveratrol dose may experience 10-fold differences in serum concentration.
Population-level RCTs average across this variance. They show "a 2 mmHg blood pressure reduction" by averaging responders and non-responders. But the wearable-obsessed biohacker wants to know: *am I* a responder? And the current answer is: you can't tell from short-term HRV or glucose data.
This knowledge gap—not evidence against resveratrol, but failure to predict individual response—is what drove the exodus.
What Remains in High-Performer Supplement Stacks Now
The compounds that survived the great 2024-2025 deprioritization are those with either: (1) rapid individual-level feedback, or (2) mechanistic evidence so robust that population-level data is considered sufficient despite lack of wearable-visible endpoints.
Magnesium is Tier 1. Sleep latency and deep sleep percentage improve measurably within days on wearables. A 2023 study in *Nutrients* (Cao et al.) confirmed that glycine-bound magnesium shows superior absorption and faster sleep-architecture effects than oxide forms.
Creatine monohydrate persists because cognitive performance can be self-tracked via reaction time apps or workplace performance metrics. A 2022 meta-analysis in *Nutrients* (Roschel et al.) confirmed that 5g daily produces measurable improvements in processing speed within 4-6 weeks—a timeframe short enough to feel like optimization, long enough to collect meaningful data.
Omega-3 supplementation is a hybrid. It has robust population-level cardiovascular data (VITAL trial, 2018; *New England Journal of Medicine*), but no wearable-visible acute effects. Wealthy biohackers now often deprioritize it unless baseline triglycerides are elevated and measurable via quarterly blood work.
Resveratrol, quercetin, and other polyphenols? They're present in the stacks of those still committed to longevity protocols, but treated as low-priority insurance rather than active optimization targets.
The Uncomfortable Truth About Biohacker Resource Allocation
There's something revealing about how this cohort optimizes. They have money. They have access to the best supplements, the best wearables, the best clinicians. Yet when given perfect information—real-time biomarker feedback—they mostly abandoned compounds that don't produce visible short-term changes.
This is rational, but it inverts a core assumption of supplement science. Much of the benefit of consistent micronutrient intake, antioxidant intake, and longevity supplementation may accrue invisibly over years. It's preventing cellular damage you never detect via HRV or glucose monitoring. The lack of a dashboard signal doesn't mean the intervention doesn't work—it means it works on a timescale beyond biohacker perception.
By optimizing for wearable visibility, this cohort may be sacrificing slow, invisible health for fast, visible biomarker changes.
What Changed Materially About Supplement Science Itself
Almost nothing, scientifically, changed about resveratrol or polyphenols between 2023 and 2025. No major trials disproved their benefits. No mechanistic studies overturned prior understanding.
What changed was the *framing of evidence standards* in optimization culture. When your feedback tool is a continuous glucose monitor, a supplement that only shows benefits in 5-year aging cohort studies becomes invisible.
The shift is less about science and more about tooling. Wearables created a new epistemic standard: if you can't measure it in real-time, it's not part of the optimization loop.
This standard is useful for some purposes. It prevents people from chasing theoretical benefits disconnected from their own individual response. But it also penalizes any intervention whose benefits are slow, invisible, or population-level.
What Actually Remains Unknown
The critical unanswered question is whether the interventions that *do* show up on dashboards—the cold plunges, the fasting windows, the sleep-timing protocols—actually deliver better long-term health than the slow, invisible compounds they've replaced.
A trader optimizing his HRV to 180 and his deep sleep percentage to 35% is measurably improving certain biomarkers. Whether that translates to better aging, lower disease risk, or extended healthspan remains to be seen. The cohort is essentially conducting a large, uncontrolled experiment in themselves.
It's possible the wearable-obsessed biohackers are capturing the best of both interventions. It's also possible they're optimizing for proxies rather than outcomes. That distinction will only become clear in 10-15 years when we have long-term data on this cohort's aging trajectories.
Until then, the shift from wine-based compounds to wearable-driven protocols remains a fascinating case study in how *tools of measurement* reshape health optimization more powerfully than new science does.
